Reflections on inositol(s) for PCOS therapy: steps toward success

References

• Stein I, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935;29:181–91
   Google Scholar
• Koivunen R, Laatikainen T, Tomás C, et al. The prevalence of polycystic ovaries in healthy women. Acta Obstet Gynecol Scand 1999;78:137–41
   PubMed Web of Science ®Google Scholar
• Nestler JE. Role of hyperinsulinemia in the pathogenesis of the polycystic ovary syndrome, and its clinical implications. Semin Reprod Endocrinol 1997;15:111–22
   PubMedGoogle Scholar
• Baillargeon JP, Iuorno MJ, Nestler JE. Insulin sensitizers for polycystic ovary syndrome. Clin Obstet Gynecol 2003;46:325–40
   PubMed Web of Science ®Google Scholar
• Genazzani AD, Lanzoni C, Ricchieri F, et al. Metformin administration is more effective when non-obese patients with polycystic ovary syndrome show both hyperandrogenism and hyperinsulinemia. Gynecol Endocrinol 2007;23:146–52
   PubMed Web of Science ®Google Scholar
• Pasquali R, Gambineri A. Insulin-sensitizing agents in polycystic ovary syndrome. Eur J Endocrinol 2006;154:763–75
   PubMed Web of Science ®Google Scholar
• Wakelam M, ed. The cell biology of inositol lipids and phosphates. Proceedings of the 2006 Biochemical Society Annual Symposium; 2006 Mar 29–30; Birmingham, United Kingdom; Biochemical Society Symposium 2007;74:1–271
   Google Scholar
• Agranoff BW. Turtles all the way: reflections on myo-inositol. J Biol Chem 2009;284:21121–6
   PubMed Web of Science ®Google Scholar
• Johnson LF, Tate ME. The structure of myo-inositol pentaphosphates. Ann N Y Acad Sci 1969;165:526–32
   PubMed Web of Science ®Google Scholar
• Raboy V. Myo-inositol-1,2,3,4,5,6-hexakisphosphate. Phytochemistry 2003;64:1033–43
   PubMed Web of Science ®Google Scholar
• Larner J, Huang LC, Tang G, et al. Insulin mediators: structure and formation. Cold Spring Harb Symp Quant Biol 1988;53:965–71
   PubMedGoogle Scholar
• Cheang KI, Baillargeon JP, Essah PA, et al. Insulin-stimulated release of d-chiro-inositol-containing inositolphosphoglycan mediator correlates with insulin sensitivity in women with polycystic ovary syndrome. Metabolism 2008;57:1390–7
   PubMed Web of Science ®Google Scholar
• Baillargeon JP, Diamanti-Kandarakis E, Ostlund RE Jr, et al. Altered d-chiro-inositol urinary clearance in women with polycystic ovary syndrome. Diabetes Care 2006;29:300–5
   PubMed Web of Science ®Google Scholar
• Iuorno MJ, Jakubowicz DJ, Baillargeon JP, et al. Effects of d-chiro-inositol in lean women with the polycystic ovary syndrome. Endocr Pract 2002;8:417–23
   PubMedGoogle Scholar
• Chiu TT, Tam PP. A correlation of the outcome of clinical in vitro fertilization with the inositol content and embryotrophic properties of human serum. J Assist Reprod Genet 1992;9:524–30
   PubMed Web of Science ®Google Scholar
• Chiu TT, Rogers MS, Law EL, et al. Follicular fluid and serum concentrations of myo-inositol in patients undergoing IVF: relationship with oocyte quality. Hum Reprod 2002;17:1591–6
   PubMed Web of Science ®Google Scholar
• Papaleo E, Unfer V, Baillargeon JP, et al. Myo-inositol in patients with polycystic ovary syndrome: a novel method for ovulation induction. Gynecol Endocrinol 2007;23:700–3
   PubMed Web of Science ®Google Scholar
• Gerli S, Papaleo E, Ferrari A, Di Renzo GC. Randomized, double blind placebo-controlled trial: effects of myo-inositol on ovarian function and metabolic factors in women with PCOS. Eur Rev Med Pharmacol Sci 2007;11:347–54
   PubMed Web of Science ®Google Scholar
• Genazzani AD, Lanzoni C, Ricchieri F, Jasonni VM. Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome. Gynecol Endocrinol 2008;24:139–44
   PubMed Web of Science ®Google Scholar
• Zacchè MM, Caputo L, Filippis S, et al. Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome. Gynecol Endocrinol 2009;25:508–13
   PubMed Web of Science ®Google Scholar
• Costantino D, Minozzi G, Minozzi E, Guaraldi C. Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double blind trial. Eur Rev Med Pharmacol Sci 2009;13:105–10
   PubMed Web of Science ®Google Scholar
• Papaleo E, Unfer V, Baillargeon JP, et al. Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. Fertil Steril 2009;91:1750–4
   PubMed Web of Science ®Google Scholar
• Unfer V, Carlomagno G, Rizzo P, et al. Myo-inositol rather than d-chiro-inositol is able to improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. Eur Rev Med Pharmacol Sci 2011;15:452–7
   PubMed Web of Science ®Google Scholar
• Harwood K, Vuguin P, DiMartino-Nardi J. Current approaches to the diagnosis and treatment of polycystic ovarian syndrome in youth. Horm Res 2007;68:209–17
   PubMed Web of Science ®Google Scholar
• Matalliotakis I, Kourtis A, Koukoura O, Panidis D. Polycystic ovary syndrome: etiology and pathogenesis. Arch Gynecol Obstet 2006;274:187–97
   PubMedGoogle Scholar
• Rice S, Christoforidis N, Gadd C, et al. Impaired insulin-dependent glucose metabolism in granulosa-lutein cells from anovulatory women with polycystic ovaries. Hum Reprod 2005;20:373–81
   PubMed Web of Science ®Google Scholar
• Carlomagno G, Unfer V, Roseff S. The D-chiroinositol paradox in the ovary. Fertil Steril 2011;95:2515–16
   PubMed Web of Science ®Google Scholar
• Carlomagno G, De Grazia S, Unfer V, Manna F. Myo-inositol in a new pharmaceutical form: a step forward to a broader clinical use. Expert Opin Drug Deliv 2012;9:267–71
   PubMed Web of Science ®Google Scholar
• Nordio M, Proietti E. The combined therapy with myo-inositol and d-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone. Eur Rev Med Pharmacol Sci 2012;16:575–81
   PubMed Web of Science ®Google Scholar
• Bevilacqua A, Carlomagno G, Gerli S, et al. Results from the international consensus conference on myo-inositol and d-chiroinositolin obstetrics and gynecology – assisted reproduction technology. Gynecol Endocrinol 2015. [Epub ahead of print]. doi: 10.3109/09513590.2015.1006616
   Google Scholar
• Unfer V, Porcaro G. Updates on the myo-inositol plus d-chiro-inositol combined therapy in polycystic ovary syndrome. Expert Rev Clin Pharmacol 2014;7:623–31
   PubMed Web of Science ®Google Scholar
• Baillargeon JP, Iuorno MJ, Jakubowicz DJ, et al. Metformin therapy increases insulin-stimulated release of d-chiro-inositol-containing inositolphosphoglycan mediator in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004;89:242–9
   PubMed Web of Science ®Google Scholar
• Nestler JE, Jakubowicz DJ, Reamer P, et al. Ovulatory and metabolic effects of d-chiro-inositol in the polycystic ovary syndrome. N Engl J Med 1999;340:1314–20
   PubMed Web of Science ®Google Scholar
• Gupta A, Jakubowicz DJ, Nestler JE. Pioglitazone therapy increases insulin-stimulated release of d-chiro-inositol-containing inositolphosphoglycan mediator in women with polycystic ovary syndrome. (Abstract) 97th annual scientific meeting of The Endocrine Society; San Diego, CA, March 5–8, 2015
   Google Scholar
• Nestler JE. Metformin for the treatment of the polycystic ovary syndrome. N Engl J Med 2008;358:47–54
   PubMed Web of Science ®Google Scholar
• Palomba S, Falbo A, Di Cello A, et al. Does metformin affect the ovarian response to gonadotropins for in vitro fertilization treatment in patients with polycystic ovary syndrome and reduced ovarian reserve? A randomized controlled trial. Fertil Steril 2011;96:1128–33
   PubMed Web of Science ®Google Scholar